Medtronic Beats Q2 Estimates, Raises Full‑Year Forecast on Heart Device Demand

Medtronic (ticker MDT) reported second‑quarter results that smashed analyst expectations and raised its full‑year outlook, as strong demand for cardiovascular devices, especially its pulsed field ablation (PFA) portfolio, drove growth. The company posted adjusted earnings per share of $1.36 — topping the consensus estimate of $1.31 — and revenue of $8.96 billion, exceeding the projected $8.87 billion. The cardiovascular division alone generated $3.44 billion in sales, up 10.8 % year‑over‑year, as PFA therapy adoption accelerated and the company appeared to be gaining market share from peers such as Boston Scientific. Medtronic’s CEO Geoff Martha stressed the company’s focus on smaller “tuck‑in” acquisitions in cardiology and neuroscience to support future growth. On the guidance front, Medtronic raised the lower bound of its adjusted profit forecast for fiscal 2026 to $5.62 per share (from $5.60) and maintained the upper end at $5.66. It also lifted its organic revenue growth forecast to roughly 5.5 % (up from around 5 %). The company remains on track to spin off its diabetes business (wearables, insulin pumps) in the first half of 2026. With older patient demographics, technological advances, and growing physician adoption all supporting demand, Medtronic appears positioned for further acceleration in the back half of the year and beyond. #Medtronic #HeartDevices #MedicalTechnology #EarningsBeat #SlimScan #GrowthStocks #CANSLIM